{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-042215","form_type":"8-K","ticker":"PTPI","cik":"0001815903","company_name":"Petros Pharmaceuticals, Inc.","filed_at":"2022-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.447268+00:00","generated_at":"2026-06-26T09:52:57.305579+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Petros Pharma reports 2021 net sales $7.8M, net loss down 56% to $9.0M","bullets":["Net sales $7.8M vs $9.6M in 2020; prescription sales fell to $4.6M due to competitive coupons.","Gross profit up 13% to $6.2M on lower write-offs and fulfillment costs; SG&A flat at $15.6M.","Net loss improved to $9.0M from $20.6M, largely from reduced fair value derivative liability.","Cash at year-end ~$24M; pursuing OTC switch for STENDRA with two self-selection studies launched.","Collaboration with Dr. Drew Pinsky to raise men's health awareness; H100 Peyronie's license expanded."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-042215","json":"https://secwatch.observer/filing/0001104659-22-042215.json","markdown":"https://secwatch.observer/filing/0001104659-22-042215.md","text":"https://secwatch.observer/filing/0001104659-22-042215.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815903/000110465922042215/0001104659-22-042215-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815903/000110465922042215/tm2211512d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T09:52:57.305579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}